Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03379363 · ClinicalTrials.gov registry record

Retrospective Chart Review Study of Pediatric Patients Treated With Korlym for Cushing Syndrome

A clinical trial, sponsored by Corcept Therapeutics.

Terminated
Registry status
2
Enrollment target

NCT03379363: Clinical Trial study, sponsored by Corcept Therapeutics.

NCT03379363 is a clinical trial that was terminated before completion, run by Corcept Therapeutics. The registered enrollment target is 2 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03379363 was terminated before completion, sponsored by Corcept Therapeutics.

TERMINATED
Registry status
2 participants
Enrollment target

Study Summary

This retrospective, multi-center, chart review study will collect patient data from medical charts of pediatric patients who have been treated with Korlym for Cushing's syndrome.

Primary Outcome

The retrospective review would analyze the drug utilization patterns of pediatric patients treated with Korlym

Trial Details

FieldValue
Enrollment Target 2 participants
Start Date 2017-09-18
Est. Completion 2018-02-12
Corcept Therapeutics

54 total trials

Why NCT03379363 stopped before completion

NCT03379363 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 2 participants, a relatively small participant target.

The record links to 0 conditions, and to 0 interventions.

NCT03379363 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03379363 about?

NCT03379363 is a clinical study titled "Retrospective Chart Review Study of Pediatric Patients Treated With Korlym for Cushing Syndrome". This retrospective, multi-center, chart review study will collect patient data from medical charts of pediatric patients who have been treated with Korlym for Cushing's syndrome.

What is the current status of trial NCT03379363?

This trial is currently terminated. The enrollment target is 2 participants. The study started on 2017-09-18. Estimated completion is 2018-02-12.

Who is sponsoring clinical trial NCT03379363?

This trial is sponsored by Corcept Therapeutics, which has 54 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03379363, the US trial registry maintained by the National Library of Medicine. NCT03379363 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.